Anzeige
Mehr »
Login
Donnerstag, 21.11.2024 Börsentäglich über 12.000 News von 677 internationalen Medien
Von Solarenergie zu digitalen Assets: Die Strategie hinter der 75-Prozent-Rallye
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DR6E | ISIN: CA60255C8850 | Ticker-Symbol: MMQ
Tradegate
21.11.24
13:19 Uhr
7,000 Euro
-0,130
-1,82 %
Branche
Rohstoffe
Aktienmarkt
Sonstige
1-Jahres-Chart
MIND MEDICINE MINDMED INC Chart 1 Jahr
5-Tage-Chart
MIND MEDICINE MINDMED INC 5-Tage-Chart
RealtimeGeldBriefZeit
6,9807,14513:25
6,9507,09013:20

Aktuelle News zur MIND MEDICINE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MoMindMed ernennt neuen Leiter für Regulierung und Qualität12
MoMindMed appoints new regulatory and quality chief6
MoMind Medicine (MindMed) Inc.: MindMed Appoints Gregg Pratt, Ph.D. as Chief Regulatory and Quality Assurance Officer218Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced...
► Artikel lesen
MIND MEDICINE Aktie jetzt für 0€ handeln
13.11.Mind Medicine Inc.: MindMed to Participate in Upcoming Investor Conferences224Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced...
► Artikel lesen
11.11.Mind Medicine (MindMed)'s (MNMD) Buy Rating Reiterated at HC Wainwright18
08.11.Mind Medicine (MindMed) Inc reports results for the quarter ended in September 30 - Earnings Summary17
07.11.Mind Medicine Inc.: MindMed Reports Third Quarter 2024 Financial Results and Business Updates293--On track to initiate the Phase 3 Voyage study of MM120 Orally Disintegrating Tablet (ODT) in Generalized Anxiety Disorder (GAD) in the fourth quarter of 2024; 12-week topline data anticipated...
► Artikel lesen
07.11.MindMed Reports Third Quarter 2024 Financial Results and Business Updates64NEW YORK--(BUSINESS WIRE)--Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain...
► Artikel lesen
07.11.Mind Medicine Inc. - 10-Q, Quarterly Report1
07.11.Mind Medicine Inc. - 8-K, Current Report2
24.10.Mind Medicine Inc.: MindMed to Host Conference Call and Webcast to Discuss Third Quarter 2024 Financial Results and Provide Business Update221Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the "Company" or "MindMed"), a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced...
► Artikel lesen
18.10.MindMed announces exchange agreement with investors15
17.10.Mind Medicine Inc. - 8-K, Current Report2
26.09.Carrie Liao Sells 2,352 Shares of Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Stock16
26.09.MindMed executive sells shares worth over $14k12
26.09.MindMed CEO Robert Barrow sells shares worth over $118,00010
26.09.Mind Medicine's chief medical officer sells shares worth over $41,0005
26.09.MindMed executive sells over $26k in company stock3
16.09.MindMed stock target trimmed, rating retained on dilution concerns8
16.09.Kursziel für MindMed-Aktie gesenkt, Kaufempfehlung trotz Verwässerungsbedenken beibehalten14
Seite:  Weiter >>
66 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1